reports
ChemoCentryx Announces Presentations at the 2022 American Society of N...
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings -- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhib...
ChemoCentryx Announces Upcoming Presentations for Orally Administered ...
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting -- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibi...
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming M...
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN). 18th European Meeting on Complement ...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference ...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022...
Chemocentryx Inc: 4 directors
Four Directors at Chemocentryx Inc sold/sold after exercising options 193,862 shares at between 50.169USD and 50.244USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all ...
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference ...
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022 SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (I...
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Tri...
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting -- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing ...
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Ne...
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor. Eu...
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx Announces Changes to its Board of Directors -- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an independent director, and Henry A. McKinnell, Jr., Ph.D., is retiring from the Board, effective May 26, 2022. “Dr. David E. Wheadon adds strength and depth to our Board,” said Thomas J. ...
ChemoCentryx Announces Presentation at the Society for Investigative D...
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa -- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Po...
ChemoCentryx to Present at the H.C. Wainwright Global Investment Confe...
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, FL. A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at A replay of the webcast will be availa...
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEO...
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculi...
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent H...
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights -- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global expansion continues with approvals in European Union (EU) and Canada; $45 million milestone received from TAVNEOS EU approval -- -- Positive Phase I data on pharmacokinetics (PK) and pharmacodynamics (PD) including ...
- Jonathan Moreland
ZION ZIONS BANCORPORATION N.A.
VKTX VIKING THERAPEUTICS
TCBI TEXAS CAPITAL BANCSHARES INC.
SXT SENSIENT TECHNOLOGIES CORPORATION
ONB OLD NATIONAL BANCORP
LLNW LIMELIGHT NETWORKS
KSS KOHL'S CORPORATION
IPG INTERPUBLIC GROUP OF COMPANIES INC.
INTC INTEL CORPORATION
HCI HCI GROUP INC.
HCA HCA HEALTHCARE INC
FFIN FIRST FINANCIAL BANKSHARES INC
FBNC FIRST BANCORP (NORTH CAROLINA)
ECL ECOLAB INC.
CCXI CHEMOCENTRYX INC
ACAD ACADIA PHARMACEUTICALS INC.
AAT AMERICAN ASSETS TRUST INC.
NCBS NICOLET BANKSHARES INC
QRHC QUEST RESOURCE HOLDING
SPOK SPOK HOLDINGS
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
SMBC SOUTHERN MISSOURI BANCORP INC.
FTV FORTIVE CORP.
PWOD PENNS WOODS BANCORP INC.
RILY B. RILEY FINANCIAL
INDT INDUS REALTY TRUST INC
AFRM AFFIRM HOLDINGS
DUOL DUOLINGO
ATAI INC.
TRST ATAI LIFE SCIENCES BV
TPST TRUSTCO BANK CORP NY
MILLENDO THERAPEUTICS
INC.
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference C...
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022 SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on May 5, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (Internati...
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from ...
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022 -- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients -- SAN CARLOS, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical da...
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Resul...
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights -- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering $45 million milestone from Vifor Pharma received in Q1 2022 -- -- Company plans to initiate clinical development for TAVNEOS in lupus nephritis (LN) and to meet with FDA on the path forward in severe h...
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Resul...
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022 MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028...
CHEMOCENTRYX sees an upgrade to Slightly Negative thanks to a better s...
The independent financial analyst theScreener just awarded an improved star rating to CHEMOCENTRYX (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 15, 20...
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Heal...
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16th at 5:00 p.m. Eastern Time. A live webcast of the presentation can be accessed through the Investors section of the Company's website at A replay of the webcast will be available on the Company's website for...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.